Cancer/Testis Antigen Expression on Mesenchymal Stem Cells Isolated from Different Tissues

• Published in: Anticancer research Vol. 30; no. 12; pp. 5023 - 5027
• Main Authors: SALDANHA-ARAUJO, Felipe, HADDAD, Rodrigo, LUCIOLA ZANETTE, Dalila, GOES DE ARAUJO, Amélia, DELGADO ORELLANA, Maristela, TADEU COVAS, Dimas, ZAGO, Marco Antonio, PANEPUCCI, Rodrigo Alexandre
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01.12.2010
• Subjects: Antigens, Neoplasm - biosynthesis; Biological and medical sciences; Fibroblasts - immunology; Humans; Immunophenotyping; Medical sciences; Melanoma-Specific Antigens; Membrane Proteins - biosynthesis; Mesenchymal Stromal Cells - immunology; Neoplasm Proteins - biosynthesis; Pericytes - immunology; Tumors; Pericyte; Cancer testis antigen; Tumor associated antigen; MAGED1; Stem cell; pericytes; Preferentially expressed antigen of melanoma; Mesenchymal cell; fibroblasts; Cancerology; mesenchymal stem cells; Isolated cell; PRAME; Fibroblast; Cancer/testis antigens
• ISSN: 0250-7005; 1791-7530

The expression of cancer/testis antigens (CTAs) on additional normal tissues or stem cells may restrict their use as cancer targets. The objective of the present study was to evaluate the mRNA levels of some CTAs in a variety of tissues. mRNA of pericytes, fibroblasts and mesenchymal stem cells (MSCs) derived from adult and fetal tissues, human umbilical vein endothelial cells, MSC-derived adipocytes, selected normal tissues and control cancer cell lines (CLs) were extracted and quantitative polymerase chain reaction was performed for MAGED1, PRAME, CTAG1B, MAGEA3 and MAGEA4. MAGED1 was expressed in all normal tissues and cells evaluated. CTAG1B was expressed at levels comparable to control CLs on MSCs derived from arterial, fetal skin, adipose tissue and saphenous vein, heart, brain and skin tissues. MAGEA4 was detected only in fibroblasts and differentiated adipocytes from MSCs, at levels comparable to the control CLs. The potential use of CTAs in immunotherapy should take into account the potential off-target effects on MSCs.